Cullen/Frost Bankers’s Myriad Genetics MYGN Stock Holding History

Cullen/Frost Bankers’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-74	Closed	-$1.81K	–	1321
2024 Q2	$1.81K	Hold	74	–	–	﹤0.01%	1122
2024 Q1	$1.58K	Hold	74	–	–	﹤0.01%	955
2023 Q4	$1.42K	Hold	74	–	–	﹤0.01%	971
2023 Q3	$1.19K	Hold	74	–	–	﹤0.01%	1101
2023 Q2	$1.72K	Buy	+74	New	+$1.61K	﹤0.01%	1058
2021 Q4	–	Sell	-856	Closed	-$28K	–	1277
2021 Q3	$28K	Hold	856	–	–	﹤0.01%	902
2021 Q2	$26K	Buy	+856	New	+$24.7K	﹤0.01%	933

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Cullen/Frost Bankers's MYGN Position: Q3 2024 in Review

Cullen/Frost Bankers sold out of Myriad Genetics (MYGN) in Q3 2024, closing a stake of 74 shares — an estimated $1.81K sold.

Cullen/Frost Bankers first reported a position in MYGN in Q2 2021 and held it in 7 quarters. The position peaked at $28K in Q3 2021. 246 funds tracked by Wall St. Rank hold MYGN as of Q3 2024.

Cullen/Frost Bankers reported no remaining Myriad Genetics position as of Q3 2024 after selling out during the quarter.
Cullen/Frost Bankers sold 74 Myriad Genetics shares in Q3 2024, an estimated $1.81K.
Cullen/Frost Bankers first reported a position in Myriad Genetics in Q2 2021 and held it in 7 quarters.
Cullen/Frost Bankers's Myriad Genetics position peaked at $28K in Q3 2021.
246 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2024.

Based on Cullen/Frost Bankers's 13F filing for Q3 2024, filed 6 Nov 2024.